| |
| |
|
| Insider
Information: |
Gasmi Mehdi |
| Relationship: |
Director |
| City: |
Menlo Park |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
274,442 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$2,450,767 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
274,442 |
|
|
| Total
Value |
$2,450,767 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
1
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -34.1%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Adverum Biotechnologies, Inc |
ADVM |
Director |
2020-07-20 |
274,442 |
2015-04-07 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
66 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ADVM |
Adverum Biotechnologies, ... |
VP, Pharmaceutical Development |
• – – |
2015-04-07 |
4 |
AS |
$38.59 |
$347,425 |
D/D |
(9,000) |
0 |
0 |
- |
|
| ADVM |
Adverum Biotechnologies, ... |
VP, Pharmaceutical Development |
• – – |
2015-04-07 |
4 |
OE |
$2.75 |
$24,750 |
D/D |
9,000 |
9,000 |
0 |
- |
|
| ADVM |
Adverum Biotechnologies, ... |
VP, Pharmaceutical Development |
• – – |
2015-04-14 |
4 |
AS |
$39.45 |
$39,448 |
D/D |
(1,000) |
0 |
0 |
- |
|
| ADVM |
Adverum Biotechnologies, ... |
VP, Pharmaceutical Development |
• – – |
2015-04-14 |
4 |
OE |
$2.75 |
$2,750 |
D/D |
1,000 |
1,000 |
0 |
- |
|
| ADVM |
Adverum Biotechnologies, ... |
VP, Pharmaceutical Development |
• – – |
2015-04-21 |
4 |
A |
$0.00 |
$0 |
D/D |
7,000 |
7,000 |
0 |
- |
|
| ADVM |
Adverum Biotechnologies, ... |
VP, Pharmaceutical Development |
• – – |
2015-04-21 |
4 |
AS |
$39.21 |
$39,211 |
D/D |
(1,000) |
0 |
0 |
- |
|
| ADVM |
Adverum Biotechnologies, ... |
VP, Pharmaceutical Development |
• – – |
2015-04-21 |
4 |
OE |
$2.75 |
$2,750 |
D/D |
1,000 |
1,000 |
0 |
- |
|
| ADVM |
Adverum Biotechnologies, ... |
VP, Pharmaceutical Development |
• – – |
2015-04-28 |
4 |
OE |
$2.75 |
$2,750 |
D/D |
1,000 |
8,000 |
0 |
- |
|
| ADVM |
Adverum Biotechnologies, ... |
VP, Pharmaceutical Development |
• – – |
2015-04-28 |
4 |
AS |
$35.67 |
$35,667 |
D/D |
(1,000) |
7,000 |
0 |
- |
|
| ADVM |
Adverum Biotechnologies, ... |
VP, Pharmaceutical Development |
• – – |
2015-05-07 |
4 |
AS |
$33.28 |
$16,638 |
D/D |
(500) |
7,000 |
0 |
- |
|
| ADVM |
Adverum Biotechnologies, ... |
VP, Pharmaceutical Development |
• – – |
2015-05-07 |
4 |
OE |
$2.75 |
$1,375 |
D/D |
500 |
7,500 |
0 |
- |
|
| ADVM |
Adverum Biotechnologies, ... |
VP, Pharmaceutical Development |
• – – |
2015-05-14 |
4 |
AS |
$35.31 |
$17,656 |
D/D |
(500) |
7,000 |
0 |
- |
|
| ADVM |
Adverum Biotechnologies, ... |
VP, Pharmaceutical Development |
• – – |
2015-05-14 |
4 |
OE |
$2.75 |
$1,375 |
D/D |
500 |
7,500 |
0 |
- |
|
| ADVM |
Adverum Biotechnologies, ... |
VP, Pharmaceutical Development |
• – – |
2015-05-21 |
4 |
AS |
$38.87 |
$19,435 |
D/D |
(500) |
7,000 |
0 |
- |
|
| ADVM |
Adverum Biotechnologies, ... |
VP, Pharmaceutical Development |
• – – |
2015-05-21 |
4 |
OE |
$2.75 |
$1,375 |
D/D |
500 |
7,500 |
0 |
- |
|
| ADVM |
Adverum Biotechnologies, ... |
VP, Pharmaceutical Development |
• – – |
2015-05-28 |
4 |
AS |
$38.02 |
$19,009 |
D/D |
(500) |
7,000 |
0 |
- |
|
| ADVM |
Adverum Biotechnologies, ... |
VP, Pharmaceutical Development |
• – – |
2015-05-28 |
4 |
OE |
$2.75 |
$1,375 |
D/D |
500 |
7,500 |
0 |
- |
|
| ADVM |
Adverum Biotechnologies, ... |
VP, Pharmaceutical Development |
• – – |
2015-06-08 |
4 |
OE |
$2.75 |
$1,375 |
D/D |
500 |
7,500 |
0 |
- |
|
| ADVM |
Adverum Biotechnologies, ... |
VP, Pharmaceutical Development |
• – – |
2015-06-08 |
4 |
AS |
$37.97 |
$19,321 |
D/D |
(500) |
7,000 |
0 |
- |
|
| ADVM |
Adverum Biotechnologies, ... |
SVP,Pharmaceutical Development |
• – – |
2015-06-15 |
4 |
AS |
$39.86 |
$19,931 |
D/D |
(500) |
7,000 |
0 |
- |
|
| ADVM |
Adverum Biotechnologies, ... |
SVP,Pharmaceutical Development |
• – – |
2015-06-15 |
4 |
OE |
$2.75 |
$1,375 |
D/D |
500 |
7,500 |
0 |
- |
|
| ADVM |
Adverum Biotechnologies, ... |
Chief Scientific Officer |
• – – |
2015-08-21 |
4 |
A |
$0.00 |
$0 |
D/D |
29,160 |
36,160 |
0 |
- |
|
| ADVM |
Adverum Biotechnologies, ... |
Chief Scientific Officer |
• – – |
2016-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
125,000 |
161,803 |
0 |
- |
|
| ADVM |
Adverum Biotechnologies, ... |
Chief Science & Tech Officer |
• – – |
2017-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
125,000 |
289,535 |
0 |
- |
|
| ADVM |
Adverum Biotechnologies, ... |
Director |
– • – |
2017-02-12 |
4 |
D |
$3.00 |
$38,379 |
D/D |
(12,793) |
276,742 |
0 |
- |
|
66 Records found
|
|
Page 1 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
